Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Romosozumab significantly improves vertebral cortical bone mass and structure compared with teriparatide, whereas both treatments increase vertebral trabecular bone mass similarly: high-resolution quantitative computed tomography analyses of randomized controlled trial results in postmenopausal women with low bone mineral density.
Journal: JBMR plus
Published: March 10, 2025
Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial.
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Published: November 24, 2020
Functional risk for fracture by safe functional motion testing: a short version of the safe functional motion test.
Journal: Therapeutic advances in musculoskeletal disease
Published: April 19, 2018
Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study.
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Published: June 29, 2017
Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.
Journal: The Journal of clinical endocrinology and metabolism
Published: February 10, 2016
A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial.
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Published: June 12, 2015
Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial.
Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial.
Journal: The lancet. Diabetes & endocrinology
Published: June 08, 2015
Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology.
Journal: Bone
Published: January 09, 2015
The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density.
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Published: December 16, 2014
Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture.
Journal: Menopause (New York, N.Y.)
Published: September 27, 2012
Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial.
Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Published: July 19, 2012
Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial.
Journal: The Journal of clinical endocrinology and metabolism
Published: June 16, 2012
Last Updated: 09/26/2026